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The purpose of this review is to summarize currently
available evidence implicating vitamin K in the
pathogenesis of vascular calcification (VC), in particular
arterial medial calcification. In doing so, we try to provide a
rationale for an interventional clinical study testing whether
vitamin K supplementation can retard VC or even affect
cardiovascular mortality in chronic kidney disease patients.
Additionally, we wish to give an overview of the current
literature indicating potential adverse effects of long-term
vitamin K antagonists in this population.
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Cardiovascular disease underlies 50% of all deaths in chronic
kidney disease (CKD) patients. Vascular calcifications (VCs),
that is, atherosclerotic intima calcifications and calcification
of media, are major contributors to mortality. Although
atherosclerotic lesions are cholesterol- and lipid-associated,
medial calcification is associated with diabetes, uremia, and
disturbed mineral metabolism. Medial calcifications often
underlie VC in CKD patients and non-invasive distinction
between intimal and medial calcification is difficult and both
may occur simultaneously.1 It is assumed that medial
calcification increases vascular stiffness resulting in left
ventricular hypertrophy, a major contributor to mortality.
Accordingly, any detection of VC has been associated with
cardiovascular mortality.2–4 Numerous factors influence VC
development.5 This review focuses on the major local
calcification inhibitor in the arterial media, the matrix-Gla
protein (MGP), a vitamin K-dependent protein. Accumulat-
ing evidence suggests that diet-induced vitamin K deficiency
or its antagonism may induce VC. Vitamin K supplementa-
tion is a safe approach but whether it can reduce CKD
complications, will require an interventional trial. Moreover,
these data imply that vitamin K antagonists in CKD patients
should only be given after a thorough assessment of its
benefits.
Matrix Gla protein: vitamin K-dependent inhibition of
calcification
Matrix-Gla protein, an approximately 10 kDa protein, is
produced and secreted by osteoclasts, chondrocytes, and
vascular smooth muscle cells (VSMCs) of the arterial media.
MGP needs to undergo post-translational g-glutamyl car-
boxylation of five glutamate residues to achieve full biological
activity. This activation depends on the availability of vitamin
K and thereby resembles the biology of the coagulation
factors II, VII, IX, X and proteins C and S. During vitamin K
deficiency MPG is not activated, under-carboxylated MGP
(ucMGP) is formed. Vitamin K replenishment then leads to
the bioactive fully carboxylated MGP (cMGP).
Complete absence of MGP in MGP/ mice led to
disturbed bone mineralization and the animals all died at
about 8 weeks after birth because of the rupture of a severely
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calcified aorta.6 In humans, a loss-of-function mutation
within the MGP gene is responsible for the Keutel syndrome,
which among others is characterized by abnormal cartilage
calcification and accelerated calcification of the aorta as well
as coronary and cerebral arteries.7 To exert its anti-
calcification actions, MGP needs to be expressed locally in
the vessel wall. Thus, the lethal phenotype of MGP/ mice
was rescued by re-expressing MGP in arterial VSMCs, but
not by an increase in circulating MPG after hepatic
overexpression.8
The mechanisms by which MGP prevents arterial
calcification are unclear. One of the potential modes of
action is a direct inhibition of calcium precipitation and
crystallization. This is probably why MGP is enriched in so-
called matrix vesicles, which are released by cells such as
VSMC. These vesicles are thought to counterbalance
potentially harmful high intracellular/intravesicular calcium
concentrations.9 Another anti-calcification mechanism is
MGP’s antagonism of the bone formation inducing bone
morphogenetic protein-2.10
The development of conformation-specific antibodies
against the two MGP subtypes led to studies in rodents
and humans, showing that the inactive form, ucMGP, is
detected in areas of VC, whereas bioactive cMGP is localized
to intact vessel walls11 (Figure 1).
In rodent studies, vitamin K depletion by coumarin
resulted in VC of the tunica media,12 that is, the major site of
MGP expression, and this could be prevented by the co-
administration of vitamin K2,
13 but not vitamin K1.
14
Growth arrest-specific 6 protein: another vitamin K-depen-
dent calcification inhibitor?
Gas6, the product of the gene growth arrest-specific 6
(GAS6), like MGP, depends on carboxylation of glutamate
residues to achieve bioactivity. In its active form, Gas6
prevents apoptosis of VSMC.15 This is relevant in the context
of VC, as apoptotic VSMC can serve as a nidus for calcium
phosphate precipitation. After warfarin administration, Gas6
could no longer phosphorylate its receptor Axl, thus blocking
the signal cascade of Gas6,16 upregulating apoptosis in
VSMC, 17 and increasing calcification of VSMC in vitro.18
However, the extent to which reduced Gas6 bioactivity
contributes to VC in vivo is currently unknown.
Besides its effects on apoptosis, Gas6 also affects
inflammation and thrombogenesis (reviewed in19).
Vitamin K: the basics
Vitamin K was discovered in the 1930s, when chicken on a
fat-free diet developed hemorrhages. Administration of
vitamin K was then shown to cure bleeding complications
in patients with hepatic and biliary diseases.
The group of K vitamins comprises phylloquinone
(vitamin K1) and several menaquinones (vitamin K2). The
synthetic forms, menadion (vitamin K3) and esterified
menadion (vitamin K4), have no importance for normal
human food. Vitamin K1 is bound to membranes
of the chloroplasts of green leafy vegetables. In contrast,
vitamin K2 is relatively rare in Western diets. The main
source of dietary vitamin K2 is fermented food such as cheese
and in particular the Japanese natto, a fermentation product
from soy beans. The mammalian intestinal flora and/or
intestinal enterocytes are also able to produce vitamin K2, but
the extent to which this contributes to the daily intake is
unknown.20,21
The individual denomination of the several isoforms of
menaquinones (MK) is dependent on the number of
isoprenoid residues in the side chain. In human food those
having 7, 8, or 9 isoprenoid groups are most common. On
account of the increased hydrophobic properties of longer
side chains, the various isoforms exhibit different half-lives.
For example, MK-4 with four isoprenoid groups has a half-
life time of 1 h and MK-7 of around 3 days.
In mammals, vitamin K serves as a redox partner in
cellular metabolism pathways of g-glutamyl carboxylations,
and a recycling mechanism helps to reduce the daily
requirement of vitamin K. The vitamin K cycle can be
effectively inhibited by coumarins such as warfarin, primarily
known as potent coagulation inhibitors (Figure 2).
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Figure 1 | Human vascular calcification and ucMGP. (a) Human
artery after von Kossa staining showing a medial lesion with
vascular calcification. (b) Immunohistochemical detection of
undercarboxylated MGP colocalizing with the medial calcification
identified in (a). Original magnification 10.
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Figure 2 | Schematic illustration of the vitamin K cycle
(modified from Stafford43).
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Both vitamin K1 and vitamin K2 catalyze the g-glutamyl
carboxylation of all vitamin K-dependent proteins, including
coagulation factors, osteocalcin, and MGP. Osteocalcin, also
called bone Gla protein, is exclusively synthesized by
osteoblasts and odontoblasts and is a regulator of bone
formation. Differences in vitamin K1 and K2 bioactivities
result from differences in enzyme affinity and tissue
distribution: K2 vitamins have a higher affinity for the
enzyme g-glutamyl carboxylase, which implies that lower
concentrations of vitamin K2 are needed to obtain a similar
activity of the g-glutamyl carboxylase compared with vitamin
K1. In terms of tissue distribution, vitamin K1 predominantly
accumulates in the liver, where it catalyzes the g-glutamyl
carboxylation of the coagulation factors. Vitamin K2 has a
more widespread tissue distribution and is also involved in
the carboxylation of MGP and osteocalcin.
The recommended daily allowance of total vitamin K is
1mg/kg per d; the estimated daily intake in a Western diet
ranges from 60 to 200 mg, of which vitamin K1 constitutes the
major part. However, only 10% of K1 is absorbed from food
given its tight binding to the chloroplast membranes. There
are no exact data on the amount of vitamin K2 intake, but it
is assumed that around 10% of the total vitamin K intake is
vitamin K2.
13 The mean daily dose is sufficient to maintain a
normal coagulation status, but is it unclear whether the dose
is sufficient to enable extrahepatic protein carboxylation.
Determination of the ratio of extrahepatic carboxylated
versus under-carboxylated vitamin K-dependent proteins,
such as osteocalcin or MGP, could serve as a biomarker to
assess whether vitamin K intake is sufficient. Indeed, with a
Western diet, the carboxylation grade of serum osteocalcin is
only about 70%, indicating suboptimal vitamin K2 concen-
trations in extrahepatic organs.11,22 The percentage of
circulating ucMGP in the healthy population is around
40%, again pointing to a relative vitamin K deficiency
(Schurgers, unpublished data).
Does vitamin K deficiency play a role in human disease?
In postmenopausal women with osteoporosis vitamin K
levels were lower in affected patients than in healthy
controls.23 Vice versa, in 72,000 women, the risk of hip
fractures was significantly lower in patients consuming
higher amounts of vitamin K.24 In double-blind, placebo-
controlled clinical trials, bone loss was reduced by 35% with
vitamin K1 over a 3-year period
25 and by 100% with vitamin
K2.
26 These studies are of relevance for the present discussion
given that increasing degrees of osteoporosis are associated
with increasing VC.27 However, this area is controversial, as
recent data do not confirm such an association.28
In the Rotterdam trial in 4800 elderly patients, low
vitamin K2 intake was associated with a higher incidence of
severe aortic calcification and increased mortality.29 In a
clinical trial in 100 postmenopausal women, the supplemen-
tation of vitamin K1 for 3 years improved vascular
compliance, distensibility, and intima media thickness
compared with placebo.30 However, a specific link between
low vitamin K2 intake leading to accelerated VC through an
increase in ucMGP has not been proven so far.
Blockade of the vitamin K metabolism with vitamin K
antagonists affects skeletal and vascular health as well. In
males receiving long-term warfarin, the odds ratio for
fractures was 30% higher in comparison with patients
without warfarin.31 Furthermore, both the prevalence and
extent of aortic valve and coronary calcifications increased
significantly in patients on coumarin.32 In hemodialysis
patients as well long-term use of warfarin was associated with
more severe aortic valve calcification.33 Finally, epidemiolo-
gical studies have identified the treatment with warfarin as a
risk factor for calciphylaxis, a severe complication in CKD
patients, which is characterized by extensive VC.34
Vitamin K levels, MGP bioactivity, and cardiovascular
calcification in CKD patients
On account of its lipophilic properties and incorporation
into lipoproteins, vitamin K is not supposed to be dialysed.
Earlier reports of a vitamin K deficiency in dialysis patients35
therefore point to a diminished dietary intake. Thus, as
discussed above, a differential assessment of carboxylated
versus under-carboxylated vitamin K-dependent proteins
may yield better insight into the vitamin K status. Indeed,
increased under-carboxylated osteocalcin levels were detected
in dialysis patients compared with healthy controls,36
pointing to subclinical vitamin K deficiency.
Data on ucMGP levels in the circulation of CKD patients
are more difficult to interpret, which is in line with the
experimental observations cited above,8 in which local
vascular but not systemically overexpressed MGP is protected
from VC. In patients, low rather than high circulating
ucMGP was a powerful predictor of coronary artery
calcification37 and ucMGP was decreased rather than
increased within the serum of CKD patients.38 One
explanation for these unexpected findings may be an
accumulation of ucMGP within the calcified vessel wall
resulting in low circulating levels.38 Alternatively, uncarboxy-
lated Gla proteins are secreted less from the cells, possibly to
avoid inactive proteins to enter the tissues. Moreover, besides
carboxylation, altered phosphorylation of MGP may, at least
in part, influence MGP levels. Three serine residues of MGP
are supposed to be phosphorylated, which seems to be
important for the secretion of this protein. As a consequence,
phosphorylated and dephosphorylated MGP are also detect-
able, probably resembling immature and mature forms of
MGP. Recent findings from Schurgers and colleagues show
that the serum levels of phosphorylated ucMGP are inversely
associated with calcification scores in patients and thus may
reflect the degree of existing VC.37,39 On the other hand,
dephosphorylated ucMGP is set free more easily in the
circulation even in the presence of extensive VC and thus may
allow better assessment of the vitamin K status.37,40 Taken
together, the assessment of MGP may be more complex
because of its several modifications and needs further
investigation to specify the relevance of each form.
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Vitamin K supplementation as a prophylaxis against VC?
At present only scant data are available to answer the above
question. The answer clearly awaits interventional outcome
studies in CKD patients. The rationale for such studies, that
is, to place CKD patients with their excessive cardiovascular
risk on Vitamin K is given below.
In a study in 190 women, the incidence of fractures was
significantly reduced in those supplemented with 45 mg
vitamin K2 per day.
41 In another Japanese study, dialysis
patients received 45 mg per day vitamin K2 over a 12-month
period, which resulted in increased serum levels of carboxy-
lated osteocalcin within 1 month.42 In rodent studies, the
therapeutic administration of vitamin K2 resulted in reduced
VC (own observations and Schurgers et al.13), but confirma-
tion in humans is lacking. However, in a pilot study in 50
dialysis patients we have recently shown that the daily
administration of 360 mg vitamin K2 resulted in a significant
increase of cMGP as well as osteocalcin (Westenfeld R et al.:
ASN Renal Week 2008, Abstract Book).
With regard to the safety of vitamin K2 supplements, no
relevant side effects have been described so far. In particular,
no thromboembolic events or shunt dysfunctions were
reported.41,42 Moreover, vitamin K substitution has been
carried out in neonates in Asia and Europe for years with no
side effects being observed.
On account of its availability for extrahepatic tissues,
vitamin K2 should be regarded as the isoform being optimal
for supplementation. The optimal dose of vitamin K2
remains to be tested. Isoforms with longer side chains, for
example, MK-7, may be the best choice given their half-life.
Schurgers et al.13 showed that 146 mg MK-7 daily significantly
increased serum levels of vitamin K2 after 14 days.
CONCLUSION
Vitamin K supplementation in the form of vitamin K2 isoforms
may be an easy intervention to counteract the relative vitamin K
deficiency observed in particular in dialysis patients. Although
such an intervention has been shown to be safe, the optimal
daily dosage and the clinical long-term benefits, in particular
reduced VC and improved bone mineral density or fracture
rates, need to be determined in clinical studies. Vice versa, the
above findings indicate that warfarin may not be neutral in the
context of VC and larger trials could elucidate the role of
warfarin, especially in CKD patients with their high risk for VC.
In addition, whether vitamin K2 supplementation is safe and
efficacious in preventing VC progress in patients with an
absolute indication for long-term vitamin K antagonist therapy
remains to be tested.
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